RCRobert Ryan Clancy

Robert Ryan Clancy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert Ryan Clancy has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Gil Wernovsky

    6 shared publications
  • James William Gaynor

    Division of Cardiothoracic Surgery, Department of Surgery, Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

    6 shared publications
  • Thomas L. Spray

    5 shared publications
  • James E. Goin

    From the Division of Neurology and the Cardiac Center, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

    3 shared publications
  • Marshall L. Jacobs

    From the Division of Neurology and the Cardiac Center, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

    3 shared publications
  • Susan A. McGaurn

    From the Division of Neurology and the Cardiac Center, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

    3 shared publications

Latest Publications

  • Early EEG improvement after ketogenic diet initiation

    by Sudha Kilaru Kessler, Paul R. Gallagher, Renée A. Shellhaas, Robert R. Clancy, A.G. Christina Bergqvist


  • Agreement Between Long-Term Neonatal Background Classification by Conventional and Amplitude-Integrated EEG

    by Robert R. Clancy, Lee Dicker, Sandy Cho, Noah Cook, Susan C. Nicolson, Gil Wernovsky, Thomas L. Spray, J. William Gaynor

    Conventional EEG (CEEG) in neonates is considered the gold standard for evaluating EEG background and detecting electrographic seizures. However, CEEG is expensive and cumbersome for long-term monitoring. A simplified method, amplitude-integrated EEG (AEEG) has been rapidly adopted to accomplish the same goals. The purpose of this study was to measure the agreement between the methods of classification in long-term EEG background assessments by CEEG and AEEG. Infants underwent CEEG monitoring after cardiac surgery and the background during four 12-hour epochs classified as "normal" or "mildly," "moderately," or "markedly" abnormal. CEEGs were converted to a single-channel AEEG and independently interpreted as "normal," "moderately abnormal," or "markedly abnormal" by standard amplitude criteria. The distributions of CEEG and AEEG interpretations were statistically compared, and the associations between CEEG and AEEG interpretations were measured. Generalized estimating equations were used to measure the effects of seizures and patient age on the agreement between AEEG and CEEG scores. Paired CEEGs and AEEGs were available for 637 epochs recorded from 179 infants. The distribution of CEEG backgrounds included 60% normal, 22% mildly abnormal, 13% moderately abnormal, and 5% markedly abnormal. The distribution of AEEG backgrounds was significantly different from CEEG and included 22% normal, 73% moderately abnormal, and 5% markedly abnormal. Nevertheless, the two techniques exhibited a significant, moderate positive association. Generalized estimating equations focusing on those with moderately abnormal AEEGs showed that younger patients with seizures were significantly more likely to have moderately or markedly abnormal CEEGs than older patients without seizures. Although there was overall significant moderate agreement between the two techniques, the distribution of backgrounds assigned by AEEG was significantly different from CEEG. Most moderately abnormal AEEGs were associated with normal or mildly abnormal CEEGs. However, the ability of moderately abnormal AEEGs to correctly predict moderately or markedly abnormal CEEG was significantly associated with the knowledge of the patient's age and the presence of seizures on CEEG.


  • Neurodevelopmental Outcomes After Staged Palliation for Hypoplastic Left Heart Syndrome

    by Sarah Tabbutt, Alex S. Nord, Gail P. Jarvik, Judy Bernbaum, Gil Wernovsky, Marsha Gerdes, Elaine Zackai, Robert R. Clancy, Susan C. Nicolson, Thomas L. Spray, et al.


  • Invited commentary

    by J. William Gaynor, Gil Wernovsky, Robert Clancy

  • Summary Proceedings From the Neurology Group on Neonatal Seizures

    by Robert R. Clancy

    One of the highest risk periods for seizures during the human life span is the first month of life. Most neonatal seizures are triggered by acute illness such as hypoxic-ischemic encephalopathy, stroke, or infection; rarely are they triggered by epilepsy per se. Seizures are the most common and important sign of acute neonatal encephalopathy, are a major risk for death or subsequent neurologic disability, and by themselves may contribute to an adverse neurodevelopmental outcome. Customary clinical practice includes visual monitoring of high-risk neonates for seizures, performance of a routine electroencephalogram (EEG) for suspicious clinical seizure activity, and empirical treatment with phenobarbital. Presently, however, there are no data that have unequivocally demonstrated the efficacy of barbiturates in the treatment of neonatal seizures. The neurology group recognizes an important need for randomized, placebo-controlled, ethically acceptable trials of phenobarbital efficacy and safety in the treatment of neonatal seizures. After exploring 3 possible frameworks for clinical trials of phenobarbital in the treatment of neonatal seizures, the neurology group ultimately focused on a multicenter, placebo-controlled, electroencephalographer-blinded study of phenobarbital versus placebo in a homogeneous group of newborns who are at high risk of developing early subclinical electroencephalographically detected neonatal seizures. Continuous video-EEG monitoring would establish the presence and number of seizures. Criteria for escape from the study to treatment are clearly defined. The proposed study could provide the first concrete evidence of treatment efficacy because (1) it examines a homogeneous patient population, (2) the recognition and quantification of seizures rests solely on the gold standard of seizure detection (EEG), and (3) the dosing of phenobarbital is matched specifically to the phenobarbital-binding characteristics of the individual treated. This study would affirm or refute the common practice of phenobarbital as the first-line treatment of neonatal seizures.


  • Electrographic Neonatal Seizures after Infant Heart Surgery

    by Robert R. Clancy, Uzma Sharif, Rebecca Ichord, Thomas L. Spray, Susan Nicolson, Sarah Tabbutt, Gil Wernovsky, J. William Gaynor

    Summary:  Purpose: Neonatal seizures are relatively common and an important early sign of acute encephalopathy in those who survive infant heart surgery. The contemporary occurrence of seizures in this setting is not fully known, and their electrographic characteristics are incompletely described. This study describes the characteristics of electrographic neonatal seizures (ENSs) in contemporary infants with congenital heart disease (CHD) surgically repaired by using cardiopulmonary bypass, with or without deep hypothermic circulatory arrest. Methods: Consecutive infants undergoing heart surgery were monitored by video‐EEG for 48 h postoperatively to establish the time of first seizure, total number of ENSs, site(s) of ENS(s) origin and other characteristics. Results: ENSs occurred in 21 (11.5%) of 183 infants. None had clinically visible seizures. The mean time to the first ENS was 21 h (range, 10–36 h). The total number of ENSs among the entire cohort was 1,429. Mean total number of ENSs per patient over a 48‐h period was 72 (range, 1–217). Phenobarbital administration was associated with a ≥50% reduction in seizure counts in five (41.7%) of 12 subjects. Conclusions: ENSs were relatively common in a large, contemporary cohort of infants after infant heart surgery. A wide variation was noted in seizure burden, but many experienced numerous seizures. Electrographic neonatal seizures are a candidate outcome end point in future neuroprotection trials in this patient population.